EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacokinetic Interaction Between Isavuconazole and Rifabutin in a Real‐World Setting

Sunish Shah, Lloyd Clarke, Tiffany Lee, Leah Georgiades, Brandon J Smith, Raman Venkataramanan iD, Ryan M Rivosecchi

Mycoses · 2026

DOI: 10.1111/myc.70157 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mycoses, 2026. Verfasst von Sunish Shah und 6 weiteren Autor:innen. Beteiligte Einrichtung: Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Pyridines, Nitriles, Triazoles, Antifungal Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Since rifabutin has less severe drug interactions, it is preferred over rifampin when administered concomitantly with azole antifungals. However, limited data exist to evaluate this interaction.

Methods

This was a single‐centre study of hospitalised patients who received concomitant isavuconazole and rifabutin prior to plasma isavuconazole therapeutic drug monitoring. Isavuconazole was administered at a standard dose of isavuconazonium sulphate 372 mg every 8 h for six doses followed by 372 mg every 24 h.

Results

Of the seven patients included, the median age (range) was 53 years (33–67), 71% (5/7) were solid organ transplant recipients and no patients had underlying cirrhosis. The median (range) corrected 24‐h steady‐state isavuconazole was 2.7 mg/L (0.7–3.7) and 86% (6/7) had an isavuconazole level > 1 mg/L. The median (range) area under the curve (AUC 24), half‐life ( T ½ ) and clearance (Cl) were 85 mg/L h (33–112), 13.1 h (6.8–17.8) and 4 L/h (3.1–10.7), respectively.

Conclusion

This study demonstrates that isavuconazole trough concentrations are often maintained above 1 mg/L despite patients being on concomitant rifabutin. However, therapeutic drug monitoring is mandatory in this setting. Further research is warranted to confirm these results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridinesNitrilesTriazolesAntifungal AgentsRifabutinHumansDrug InteractionsAdultMiddle AgedFemaleAgedMaleDrug Monitoring

Stichwörter der Autor:innen

isavuconazolerifabutinrifampintherapeutic drug monitoring

Substanzen

isavuconazolePyridinesNitrilesTriazolesAntifungal AgentsRifabutin

Autor:innen und Institutionen

  • Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • InsightRX, San Francisco, California, USA.
  • Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

ORCID-Profile: Raman Venkataramanan

Zitieren

APA

Shah, S., Clarke, L., Lee, T., Georgiades, L., Smith, B. J., Venkataramanan, R., & Rivosecchi, R. M. (2026). Pharmacokinetic Interaction Between Isavuconazole and Rifabutin in a Real‐World Setting. Mycoses. https://doi.org/10.1111/myc.70157

Vancouver

Shah S, Clarke L, Lee T, Georgiades L, Smith BJ, Venkataramanan R, et al. Pharmacokinetic Interaction Between Isavuconazole and Rifabutin in a Real‐World Setting. Mycoses. 2026. doi:10.1111/myc.70157

BibTeX
@article{Shah2026,
  author = {Shah, Sunish and Clarke, Lloyd and Lee, Tiffany and Georgiades, Leah and Smith, Brandon J and Venkataramanan, Raman and Rivosecchi, Ryan M},
  title = {Pharmacokinetic Interaction Between Isavuconazole and Rifabutin in a Real‐World Setting},
  journal = {Mycoses},
  year = {2026},
  doi = {10.1111/myc.70157}
}
Kostenlos starten →